Virologic outcomes of switching to boosted darunavir plus dolutegravir with respect to history of drug resistance

OBJECTIVE: The DUALIS study showed that switching to boosted darunavir (bDRV) plus dolutegravir (DTG; 2DR) was non-inferior to continuous bDRV plus 2 nucleoside/nucleotide reverse-transcriptase inhibitors (NRTIs; 3DR) in treatment-experienced virologically suppressed people living with HIV (PLWH). W...

Descripción completa

Detalles Bibliográficos
Autores principales: Wolf, Eva, Boesecke, Christoph, Balogh, Annamaria, Bidner, Helen, Cordes, Christiane, Heiken, Hans, Krznaric, Ivanka, Kümmerle, Tim, Stellbrink, Hans-Jürgen, Schneider, Jochen, Spinner, Christoph D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Short Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8425038/
https://www.ncbi.nlm.nih.gov/pubmed/34496848
http://dx.doi.org/10.1186/s12981-021-00384-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8425038/
https://www.ncbi.nlm.nih.gov/pubmed/34496848
http://dx.doi.org/10.1186/s12981-021-00384-6

Ejemplares similares